Newleos Therapeutics
Newleos Therapeutics is a clinical-stage biotechnology company co-founded by Longwood Fund and seasoned CNS drug-development leaders, headquartered in Boston, Massachusetts. Its pipeline, licensed from Roche, develops oral small-molecule therapeutics targeting GABAA-gamma1, V1a, TAAR1 and GABAA-alpha5 mechanisms, with first- or best-in-class potential for general anxiety, social anxiety, substance use disorders, and cognitive impairment. Newleos is a pharmaceutical R&D company with no public developer or API product surface; this profile captures its corporate web presence for the API Evangelist network.
Index entry only — little beyond a description and a link, and nothing machine-readable enough for an agent to act on without a human reading the site first.
Newleos Therapeutics is tracked in the API Evangelist network. This page is the human-readable profile that sits on top of the machine-readable index we maintain at apis.io.
Every provider in the network is reduced to the same set of machine-readable artifacts — OpenAPI contracts, event specifications, GraphQL schemas, runnable collections, pricing and rate-limit signals, security posture, OAuth scopes, and the agent surfaces (MCP servers and skills) that let software drive the API on its own. We profile them because the interface is the part of a company you can actually inspect: it is a truer signal of what a provider does than any marketing page. From those artifacts we compute the Kin Score — Newleos Therapeutics scores 12.3/100 (minimal), with a separate agent-readiness read of 0/100 (human only). The full breakdown is below, followed by every artifact we hold — each card links through to its machine-readable definition on apis.io.
Kin Score
This is the API Evangelist rating — a single, repeatable read computed from the artifacts on this page. Green fill is points earned; the red track is points possible, so every bar shows earned-versus-possible at a glance.
Resources
Every other property we hold for Newleos Therapeutics — documentation, portals, status pages, policies, and corporate surface — grouped by the job it does, following the integrator's arc from getting started to running in production.
Commercial 2
Pricing, plans, and the legal terms of use
Company 2
The organization behind the API
Newleos Therapeutics is in the network as a tracked entity. We haven't yet indexed a public API surface for it — when one is published, the artifacts, score, and agent-readiness read will appear here automatically. The source repository is where that profile is built.
← All providers · Data indexed from github.com/api-evangelist/newleos-therapeutics · machine-readable index on apis.io